drugset / Trial / NCT00149877

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

NCT00149877

Phase 4 Completed 250 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a new class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study is to investigate the efficacy, safety and tolerability of tegaserod on bowel habits in patients with CC.

Timeline

Start
2004-04
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegaserod Small molecule

Indications